Entecavir for Patients with Hepatitis B Decompensated Cirrhosis in China: A meta-analysis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, F Y ^a   Li, B ^b   Li, Y ^a   Liu, H ^b   Qu, W D ^c   Xu, H W ^b   Qi, J N ^b   Qin, C Y ^b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^c The Central Hospital of Tai'an   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENTECAVIR; GUANINE; VIRUS DNA;

ANALOGS AND DERIVATIVES; CHINA; COMPLICATION; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CIRRHOSIS; META ANALYSIS;

ANTIVIRAL AGENTS; CHINA; DNA, VIRAL; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER CIRRHOSIS;

EID: 84986275159     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep32722     Document Type: Article

References (43)

1. European Association for the Study of the Liver. et al. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57, 167-185, doi: 10.1016/j.jhep.2012.02.010 (2012).
2. Hou, J. et al. The guideline of prevention and treatment for chronic hepatitis B: a 2015 update. Zhonghua gan zang bing za zhi 23, 888-905, doi: 10.3760/cma.j.issn. 1007-3418.2015.12.002 (2015).
3. Keating, G. M. Entecavir: a review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease. Drugs 71, 2511-2529, doi: 10.2165/11208510-000000000-00000 (2011).
4. Chang, T.-T. et al. A Comparison of Entecavir and Lamivudine for HBeAg-Positive Chronic Hepatitis B. New England Journal of Medicine 354, 1001-1010, doi: doi: 10.1056/NEJMoa051285 (2006).
5. Suzuki, F. et al. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients. Journal of gastroenterology and hepatology 23, 1320-1326, doi: 10.1111/j.1440-1746.2008.05455.x (2008).
6. Schiff, E. et al. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. The American journal of gastroenterology 103, 2776-2783, doi: 10.1111/j.1572-0241.2008.02086.x (2008).
7. Schiff, E. R. et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clinical gastroenterology and hepatology: the official clinical practice journal of the American Gastroenterological Association 9, 274-276, doi: 10.1016/j.cgh.2010.11.040 (2011).
8. Liaw, Y. F. et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology (Baltimore, Md.) 54, 91-100, doi: 10.1002/hep.24361 (2011).
9. Yang, J., Z, X. Wang H. Antiviral effects of entecavir in patients with hepatitis B virus-induced decompensated liver cirrhosis. Jiangxi Medical Journal, 477-480 (2012).
10. Peng, H. et al. Efficacy of lamivudine combined with adefovir dipivoxil versus entecavir monotherapy in patients with hepatitis B-associated decompensated cirrhosis: A meta-analysis. Journal of clinical pharmacology 54, 189-200, doi: 10.1002/jcph.181 (2014).
11. Ye, X. G. & Su, Q. M. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World journal of gastroenterology 19, 6665-6678, doi: 10.3748/wjg.v19.i39.6665 (2013).
12. Singal, A. K. & Fontana, R. J. Meta-analysis: oral anti-viral agents in adults with decompensated hepatitis B virus cirrhosis. Aliment Pharmacol Ther 35, 674-689, doi: 10.1111/j.1365-2036.2011.04990.x (2012).
13. Liaw, Y.-F. et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology (Baltimore, Md.) 53, 62-72, doi: 10.1002/hep.23952 (2011).
14. Lai, C.-L. et al. Entecavir for HbeAgnegative chronic hepatitis B. A randomized comparison of entecavir to lamivudine for treatment of HBeAg-negative chronic hepatitis B in nucleoside-naive patients. N Engl J Med, 1011-1020 (2006).
15. Amini-Bavil-Olyaee, S., Herbers, U., Luedde, T., Trautwein, C. & Tacke, F. Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains. Journal of viral hepatitis 18, 804-814, doi: 10.1111/j.1365-2893.2010.01378.x (2011).
16. Chen, F. Z. et al. Efficacy of entecavir for patients with HBV related decompensated cirrhosis. J Clini Hepatol 26, 608-609,612 (2010).
17. Feng, J. et al. Effect of an antiretroviral therapy to hepatitis B cirrhosis. China Prac Med, 13-14 (2008).
18. Zhang, D. H. et al. Effect of antiretroviral therapy to hepatitis B cirrhosis. Modern Preventive Medicine 751-753 (2011).
19. XM, H. Clinical efficacy of entecavir for 36 patients with HBV related decompensated cirrhosis. China Health Care & Nutrition 03, 1 (2014).
20. YL, B. Comparison of the efficacies of lamivudine combined with adefovir dipivoxil de novo and entecavir alone in patients with hepatitis B virus-related decompensated cirrhosi. Da Lian medical university (2014).
21. JB, S. et al. Clinical Observation of Entecavir in the Treatment of Decompensated Cirrhoti Patient with HBV for 96 weeks. Guide of China Medicine 11-13 (2010).
22. Y, X. Comparison on effect between telbivudine combined with adefovir and entecavir in treatment of patient with hepatitis B virusrelated decompensated cirrhosis. Journal of Hubei University of Science and Technology(Medical Sciences) 387-390 (2013).
23. Lin, X. S., X, F. & Wang, X. Y. Efficacy of Entecavir therapy in decompensated HBV cirrhosis. Clin Med J Metal Indus, 257-258 (2011).
24. Han, Z. Q. et al. The effect of entecavir for HBV related decompensated cirrhosis. J Clin Hepatol, 54-56 (2009).
25. Higgins, J. P. T. G. S. 9.4 Summarizing effects across studies [updated March 2011]. www.handbook.cochrane.org. (Date of acess: 27/7/2016) (2011).
26. Higgins JPT, T. S. Quantifying heterogeneity in a Meta analysis. Statistics in Medicine 21, 1539-1558 (2002).
27. Higgins, J. P. et al. Measuring inconsistency in Meta analyses. BMJ 327, 557-560 (2003).
28. Lau, J. et al. The case of the misleading funnel plot. BMJ 333, 597-600 (2006).
29. J, Y. & HZ, F. Comparison of efficacy of nucleot(s)ide analogues in patients with hepatitis B virus-induced decompensated cirrhosis. Medical Innovation of China, 1-2 (2012).
30. Ren, W. X., J, J. & Liu, M. Curative effect of entecavir treatment for decompensated cirrhosis resulting from chronic hepatitis B(48 weeks report). Chinese Journal of Coal Industry Medicine, 176-178 (2014).
31. Luo, H. B., H, Z. & Guo, J. W. Study on 48-week treatment of entecavir in patients with decomensated hepatitis B-induced cirrhosis. J Clin Hepatol, 121-123 (2009).
32. Ning, Z. H. et al. he effect of entecavir for HBV DNA positive decompensated cirrhosis. Clin Medical Herald, 88-89 (2009).
33. FL, Z. The effects of entecavir for HBV related decompensated cirrhosis. J Med Theor & Prac, 2454-2455 (2011).
34. RL, Z. Clinical observation of entecavir for HBV related decompesnsated cirrhosis. Journal of Clinical Medicine in Practice, 59-60 (2010).
35. Guo, Y. M. & S, Z. Guo CY. Entecavir for the treatment of hepatitis B with decompensated cirrhosis. Med J NDFNC, 14-15 (2014).
36. H, L. Entecavir for hepatitis B decompensated liver cirrhosis. China Prac Med 159-160 (2009).
37. Feng, J. et al. Effect of an antiretroviral therapy to hepatitis B cirrhosis. China Prac Med, 13-14 (2008).
38. L, Y. Efficacy and safety of entecavir for patients with HBV related decompensated cirrhosis. Med Theor & Prac, 909-910 (2015).
39. Gulizireo Maola. Analysis of the clinical effect of entecavir treatment of hepatitis B decompensated liver cirrhosis. China & Foreign Medical Treatment, 131-133 (2015).
40. J, Z. Efficacy of entecvir for patients with HBV related decompensated liver cirrhosis. Chin J Mod Drug Appl, 71-72 (2014).
41. ZY, Z. Efficacy and safety of entecavir for patients with HBV-related decompensated liver cirrhosis. Zhongguo shiyong xiangcun yisheng zazhi 21, 2 (2014).
42. MX, L. Efficacy of entecavir for patients with HBV related decompensated liver cirrhosis. Mod Diagn Treat, 2717-2718 (2014).
43. XL, Z., CX, W. & CY, L. Observation of clinical effective of entecavir in treatment of patients with hepatitis B decompensated cirrhosis. Jilin Medicine, 3242-3243 (2015).